QS Investors LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 159,008 shares of the biopharmaceutical company’s stock after acquiring an additional 7,483 shares during the quarter. QS Investors LLC owned 0.10% of Amicus Therapeutics worth $2,288,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $154,000. Engineers Gate Manager LP purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $155,000. Neuberger Berman Group LLC bought a new position in shares of Amicus Therapeutics in the third quarter worth approximately $196,000. Great West Life Assurance Co. Can grew its holdings in shares of Amicus Therapeutics by 40.2% in the third quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 4,145 shares during the last quarter. Finally, Sterling Capital Management LLC bought a new position in shares of Amicus Therapeutics in the third quarter worth approximately $218,000.
Several research analysts have recently issued reports on FOLD shares. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Cowen restated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $19.06.
Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $14.50 on Tuesday. The company has a quick ratio of 5.53, a current ratio of 5.60 and a debt-to-equity ratio of 0.47. Amicus Therapeutics, Inc. has a fifty-two week low of $6.41 and a fifty-two week high of $17.40. The stock has a market cap of $2,739.83, a P/E ratio of -7.92 and a beta of 1.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.11). The company had revenue of $14.73 million during the quarter, compared to the consensus estimate of $14.50 million. Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. research analysts forecast that Amicus Therapeutics, Inc. will post -1.26 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “QS Investors LLC Boosts Holdings in Amicus Therapeutics, Inc. (FOLD)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2018/03/20/qs-investors-llc-boosts-holdings-in-amicus-therapeutics-inc-fold.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.